VIDEO: Short- and long-term data show favorable outcomes for Miebo

ByJohn D. Sheppard, MD, MMSc

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective from the World Ophthalmology Congress, John D. Sheppard, MD, MMSc, FACS, of Virginia Eye Consultants discusses clinical trial data for Miebo for the treatment of dry eye disease.

Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) was investigated for 8 weeks in the phase 2 SEECASE trial and the phase 3 GOBI and MOJAVE trials, as well as for 52 weeks in the KALAHARI safety trial.

“With these results, we have favorable safety, efficacy and tolerability outcomes at week 8 and week 52,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Racine L, et al. Perfluorohexyloctane ophthalmic solution is safe and efficacious for dry eye disease: a review of clinical trials. Presented at: World Ophthalmology Congress; Aug. 16-19, 2024; Vancouver, British Columbia.

Disclosures: Sheppard reports consulting for Bausch + Lomb and Novaliq.

Read more

VIDEO: Short- and long-term data show favorable outcomes for Miebo

Related Content